Evidence map›Paper›PMID 21622623›Full record

ArticleMolecular cancer research : MCR2011

HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells.

Xiaohua Li, Alexander Kaplun, Fulvio Lonardo, Elisabeth Heath, Fazlul H Sarkar, Jonathan Irish, Wael Sakr, Shijie Sheng

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Tumor suppressor maspin as a modulator of host immune response to cancer.Bosnian journal of basic medical sciences · 2015
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Xiaohua LiWayne State University School of Medicine, 540 East Canfield Avenue, Detroit, Michigan 48201, USA.
Alexander Kaplun
Fulvio Lonardo
Elisabeth Heath
Fazlul H Sarkar
Jonathan Irish
Wael Sakr
Shijie Sheng
Wayne State University · USThe Barbara Ann Karmanos Cancer Institute · US

Funding

The therapeutic potential of maspin in prostate cancerR01CA084176 · NCI · WAYNE STATE UNIVERSITY · PI SHENG, SHIJIE · 2001 to 2011
$2.7M
A Role of Novel Serpin Maspinin Prostate Tumor/Bone InteractionR01CA127735 · NCI · WAYNE STATE UNIVERSITY · PI SHENG, SHIJIE · 2008 to 2012
$1.5M
Stratifying the progression and prognosis of lung cancer subtypes with tumor suppR21CA154319 · NCI · WAYNE STATE UNIVERSITY · PI LONARDO, FULVIO BRUNO, SHENG, SHIJIE · 2010 to 2011
$326k
NCI NIH HHS CA084176NCI NIH HHS CA127735NCI NIH HHS CA154319NCI NIH HHS R01 CA084176NCI NIH HHS R01 CA127735NCI NIH HHS R21 CA154319
6 · The paper itself

Abstract

Both maspin and glutathione S-transferase pi (GSTp) are implicated as tumor suppressors and downregulated in human prostate cancer. It is well established that GSTp downregulation is through DNA methylation-based silencing. We report here that maspin expression in prostate cancer cell line DU145 reversed GSTp DNA methylation, as measured by methylation- specific PCR, MethyLight assay, and bisulfite sequencing. The effect of maspin on GSTp expression was similar to that of the combination of a synthetic histone deacetylase (HDAC) inhibitor and DNA methylation inhibitor 5-aza-2'-deoxycytidine. Maspin expression also led to an increased level of acetylated histone 3, decreased level of methyl transferase, and methyl-CpG-binding domain proteins at the site of demethylated GSTp promoter DNA. Earlier, we have shown that maspin inhibits HDAC1. In PC3 cells, where both maspin and GSTp are expressed at a reduced level, maspin knockdown led to a significant reduction in GSTp expression, whereas dual knockdown of maspin and HDAC1 barely increased the level of GSTp expression. Thus, HDAC1 may play an essential role in cellular response to maspin-mediated GSTp desilencing. Maspin has been shown to increase tumor cell sensitivity to drug-induced apoptosis. Interestingly, GSTp reexpression in the absence of maspin expression perturbation blocked the phosphorylation of histone 2A.X, the induction of hypoxia-induced factor 1α (HIF-1α), and cell death of LNCaP cells under oxidative stress. Because DNA hypermethylation-based silencing may couple with and depend on histone deacetylation, our study suggests that endogenous HDAC inhibition by maspin may prevent pathologic gene silencing in prostate tumor progression.

Indexed as

CarcinomaCell Line, TumorCell SurvivalGene SilencingGlutathione S-Transferase piHistone Deacetylase 1Histone Deacetylase InhibitorsHumansHydroxamic AcidsMaleProstatic NeoplasmsSerpinsVorinostatGlutathione S-Transferase piHDAC1 protein, humanHistone Deacetylase 1Histone Deacetylase InhibitorsHydroxamic AcidsSERPIN-B5SerpinsVorinostat

Identifiers

PMID21622623
PMCPMC3612175
OpenAlexW2156937478

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.